Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Pays Arvinas $50m To Form Protein Degrader R&D Pact

Executive Summary

The partnership gives the German major another potential source of drugs to treat cardiovascular, oncological and gynecological diseases.

Advertisement

Related Content

Gilead Dives Into Protein Degradation With Nurix Pact
Deal Watch: Vertex Expands Gene-Editing Efforts With A Pair Of Deals
Vertex Targeting Protein Degradation In $1bn Kymera Deal
Deal Watch: Genentech Expands Upon Arvinas PROTAC Collaboration

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125338

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel